CLINICAL_TRIALS
trial_result
· 2014-12-25
Clinical Trial Update: BAY43-9006 Phase II Study for Renal Cell Carcinoma [Phase 2]
Summary
Phase II study of BAY43-9006 (sorafenib) for renal cell carcinoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED